Hong Kong · Delayed Price · Currency is HKD Immunotech Biopharm Company Description
Immunotech Biopharm Ltd, a cellular immunotherapy biopharmaceutical company, focuses on the research, development, and commercialization of T cell immunotherapy products for the treatment of cancers in the People’s Republic of China.
The company’s core product is EAL, a multi-target cellular immunotherapy product that is in Phase III clinical trials for the prevention of postsurgical recurrence of liver cancer.
It also develops 6B11-OCIK injection that is in Phase I clinical trial for ovarian cancer; CAR-T-19 injection product for B-cell acute lymphoblastic leukaemia; RC19D2 for relapsed and refractory diffuse large B-cell lymphoma; and TCR-T cell series products to treat solid tumors.
In addition, the company develops pre-clinical products, such as aT19 to treat hematologic malignancies; YT003 and YT008 for post transplantation infections; YT007 for solid tumors; and VAC-aT19 for hematologic malignancies.
Immunotech Biopharm Ltd was founded in 2006 and is headquartered in Beijing, the People’s Republic of China.
| Country | Cayman Islands |
| Founded | 2006 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 173 |
| CEO | Jian Zhang |
Contact Details
Address: Guosheng Technology Park Beijing China | |
| Website | eaal.net |
Stock Details
| Ticker Symbol | 6978 |
| Exchange | Hong Kong Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| ISIN Number | KYG4721A1004 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Jian Zhang | Acting Chief Executive Officer and Senior Vice President |
| Zheng Tan | Executive Chairman |
| Dr. Yu Zhang | Chief Scientist |
| Shui Bing Leung A.C.S. | Company Secretary |